PPAR-γ agonists:: therapeutic role in diabetes, inflammation and cancer

被引：342

作者：

Murphy, GJ

Holder, JC

机构：

[1] SmithKline Beecham Pharmaceut, Dept Vasc Biol, MFSPIN, Harlow CM19 5AD, Essex, England

[2] SmithKline Beecham Pharmaceut, Mol Toxicol Grp, MFSPIN, Harlow CM19 5AD, Essex, England

来源：

TRENDS IN PHARMACOLOGICAL SCIENCES | 2000年 / 21卷 / 12期

关键词：

D O I：

10.1016/S0165-6147(00)01559-5

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The recent development of a novel class of insulin-sensitizing drugs, the thiazolidinediones (TZDs), represents a significant advance in antidiabetic therapy. One key mechanism by which these drugs exert their effects is by activation of the peroxisome proliferator activated receptor gamma (PPAR-gamma), a member of the nuclear receptor family. Evidence supporting this mechanism of action of the TZDs will be reviewed in this article. Recent data suggests that PPAR-gamma agonists might also have therapeutic potential in the treatment of inflammatory diseases and certain cancers.

引用

收藏

页码：469 / 474

页数：6

相关论文

共 59 条

[1] Activators of peroxisome proliferator-activated receptor γ have depot-specific effects on human preadipocyte differentiation [J].

Adams, M ;

Montague, CT ;

Prins, JB ;

Holder, JC ;

Smith, SA ;

Sanders, L ;

Digby, JE ;

Sewter, CP ;

Lazar, MA ;

Chatterjee, VKK ;

O'Rahilly, S .

JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (12) :3149-3153

[2] PPARγ is required for placental, cardiac, and adipose tissue development [J].

Barak, Y ;

Nelson, MC ;

Ong, ES ;

Jones, YZ ;

Ruiz-Lozano, P ;

Chien, KR ;

Koder, A ;

Evans, RM .

MOLECULAR CELL, 1999, 4 (04) :585-595

[3] Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension [J].

Barroso, I ;

Gurnell, M ;

Crowley, VEF ;

Agostini, M ;

Schwabe, JW ;

Soos, MA ;

Maslen, GL ;

Williams, TDM ;

Lewis, H ;

Schafer, AJ ;

Chatterjee, VKK ;

O'Rahilly, S .

NATURE, 1999, 402 (6764) :880-883

[4]

BODEN G, 1996, DIABETES, V45, P3

[5] A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-γ reverses the diabetic phenotype of the Zucker diabetic fatty rat [J].

Brown, KK ;

Henke, BR ;

Blanchard, SG ;

Cobb, JE ;

Mook, R ;

Kaldor, I ;

Kliewer, SA ;

Lehmann, JM ;

Lenhard, JM ;

Harrington, WW ;

Novak, PJ ;

Faison, W ;

Binz, JG ;

Hashim, MA ;

Oliver, WO ;

Brown, HR ;

Parks, DJ ;

Plunket, KD ;

Tong, WQ ;

Menius, JA ;

Adkison, K ;

Noble, SA ;

Willson, TM .

DIABETES, 1999, 48 (07) :1415-1424

[6] Troglitazone action is independent of adipose tissue [J].

Burant, CF ;

Sreenan, S ;

Hirano, KI ;

Tai, TAC ;

Lohmiller, J ;

Lukens, J ;

Davidson, NO ;

Ross, S ;

Graves, RA .

JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (11) :2900-2908

[7] Thiazolidinediones: a new class of antidiabetic drugs [J].

Day, C .

DIABETIC MEDICINE, 1999, 16 (03) :179-192

[8] THE TRIUMVIRATE - BETA-CELL, MUSCLE, LIVER - A COLLUSION RESPONSIBLE FOR NIDDM [J].

DEFRONZO, RA .

DIABETES, 1988, 37 (06) :667-687

[9] Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-γ ligand troglitazone in patients with liposarcoma [J].

Demetri, GD ;

Fletcher, CDM ;

Mueller, E ;

Sarraf, P ;

Naujoks, R ;

Campbell, N ;

Spiegelman, BM ;

Singer, S .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (07) :3951-3956

[10] The peroxisome proliferator-activated receptors at the cross-road of diet and hormonal signalling [J].

Desvergne, B ;

Ijpenberg, A ;

Devchand, PR ;

Wahli, W .

JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1998, 65 (1-6) :65-74

← 1 2 3 4 5 6 →